Summary
| ValidaTe enables characterization of efficacy and safety of T-cell drug candidates in days rather than months | |
| The breakthrough speed and unprecedented density of data processed can give partner companies a competitive advantage | |
| New high-throughput microarray technology for label-free characterization of drug candidate interactions can significantly accelerate development in immuno-oncology |
BioCopy AG introduces ValidaTe, an innovative, proprietary platform based on microarrays for the highly parallelized screening of drug candidates for T-cell therapy. ValidaTe is now available to biopharmaceutical companies.
With ValidaTe, about 5,000 protein-protein binding interactions are characterized simultaneously in one hour on one chip. Thus, ValidaTe chips can mirror the complexity of the human immune system. Drug candidates can be identified and drug leads can be validated instantly by screening thousands of peptide-HLA complexes placed on a thumbnail-sized surface. This parallel measurement of binding interactions is based on a proprietary label-free detection technology, which delivers highly accurate and detailed time-resolved kinetic data sets.
ValidaTe significantly shortens the time-consuming and laborious drug discovery and validation phase for novel T-cell therapies. It can provide a decisive head start in drug development, setting new benchmarks for speed and efficiency.
With this ground-breaking technology, biopharmaceutical companies can characterize and validate the efficacy and safety of T-cell drug candidates within days instead of months. The ValidaTe array can be tailored to measure the active structures of individual drug candidates for T-cell therapeutics, such as TCR-bispecifics or TCR-T-cells.
Product enhancements in 2022 include an expanded array capacity of 10,000 spots and cell-based formats.
For further information on ValidaTe, read more about it under T-cell therapy.
Binding curves in action
On the left this video shows the interaction of an analyte (TCR) with a pHLA microarray containing over 5000 individual spots. We can observe the kinetic binding of the TCR as well as the additional primary and secondary antibody steps to the pHLA spots. All of this happens label-free. The corresponding binding curve can be seen on the right.
The real-time measurement takes about an hour and includes all 5000 individual spots. To make the video easier to watch, we edited it to show only 4 of the 5000 binding curves in 50 seconds.
The ultra-high throughput of this array is unmatched and opens up completely new possibilities for drug development.
Contact
Dr. Claudia Duppé
presse@biocopy.de